Schilke Tobin — SEC insider filings

SEC reporting owner CIK 1678984. 42 insider filings on record with FilingPulse; latest filed 2026-11-17.

Transaction summary — filings shown

Covers all 42 filings on record, filed 2020-10-02 to 2026-11-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Revance Therapeutics, Inc. (RVNC)CFO35—14 legs · 71,686 sh · $2,065,98538
Crinetics Pharmaceuticals, Inc. (CRNX)Chief Financial & Infra. Ofcr.5—1 leg · 6,713 sh · $266,3059
Lexeo Therapeutics, Inc. (LXEO)Director2——1

Insider filings — Schilke Tobin

FiledFormIssuerReported transactionsSource
2026-11-173Lexeo Therapeutics, Inc. (LXEO)Holdings only — no transactions reportedEDGAR
2026-11-174Lexeo Therapeutics, Inc. (LXEO)Grant/award (A): 70,000 (derivative) @ $0EDGAR
2026-09-014Crinetics Pharmaceuticals, Inc. (CRNX)Disposition to issuer (D): 7,956 @ $85 · Disposition to issuer (D): 71,471 @ $85 · Disposition to issuer (D): 80,000 (derivative) @ $51.25 · Disposition to issuer (D): 50,000 (derivative) @ $41.21EDGAR
2026-08-244Crinetics Pharmaceuticals, Inc. (CRNX)Grant/award (A): 471 @ $0EDGAR
2026-03-044Crinetics Pharmaceuticals, Inc. (CRNX)Sale (S): 6,713 @ $39.67EDGAR
2026-02-254Crinetics Pharmaceuticals, Inc. (CRNX)Grant/award (A): 32,000 @ $0 · Grant/award (A): 50,000 (derivative) @ $0EDGAR
2025-03-114Crinetics Pharmaceuticals, Inc. (CRNX)Grant/award (A): 52,000 @ $0 · Grant/award (A): 80,000 (derivative) @ $0EDGAR
2025-02-064Revance Therapeutics, Inc. (RVNC)Code (U): 97,999 @ $3.65 · Disposition to issuer (D): 103,555 · Grant/award (A): 20,883 @ $0 · Disposition to issuer (D): 20,883EDGAR
2025-02-054Revance Therapeutics, Inc. (RVNC)Grant/award (A): 6,888 @ $0EDGAR
2025-01-034Revance Therapeutics, Inc. (RVNC)Grant/award (A): 1,000 @ $2.18EDGAR
2024-07-024Revance Therapeutics, Inc. (RVNC)Grant/award (A): 1,000 @ $2.18EDGAR
2024-03-194Revance Therapeutics, Inc. (RVNC)Tax withholding (F): 3,822 @ $5.30 · Sale (S): 9,361 @ $5.04EDGAR
2024-03-044Revance Therapeutics, Inc. (RVNC)Grant/award (A): 17,447 @ $0EDGAR
2024-02-024Revance Therapeutics, Inc. (RVNC)Grant/award (A): 96,667 @ $0 · Grant/award (A): 145,001 (derivative) @ $0EDGAR
2024-01-034Revance Therapeutics, Inc. (RVNC)Grant/award (A): 434 @ $7.47EDGAR
2023-08-154Revance Therapeutics, Inc. (RVNC)Grant/award (A): 22,620 @ $0 · Tax withholding (F): 11,215 @ $18.91EDGAR
2023-07-054Revance Therapeutics, Inc. (RVNC)Grant/award (A): 769 @ $15.61 · Sale (S): 1,701 @ $25.04EDGAR
2023-06-054Revance Therapeutics, Inc. (RVNC)Sale (S): 2,701 @ $30.57 · Sale (S): 500 @ $31EDGAR
2023-05-164Revance Therapeutics, Inc. (RVNC)Grant/award (A): 42,349 @ $0 · Sale (S): 21,401 @ $34.55EDGAR
2023-05-024Revance Therapeutics, Inc. (RVNC)Sale (S): 3,201 @ $31.70EDGAR
2023-04-044Revance Therapeutics, Inc. (RVNC)Sale (S): 3,201 @ $32.15EDGAR
2023-03-174Revance Therapeutics, Inc. (RVNC)Tax withholding (F): 3,739 @ $30.65EDGAR
2023-03-094Revance Therapeutics, Inc. (RVNC)Grant/award (A): 42,349 @ $0 · Sale (S): 18,517 @ $31.59EDGAR
2023-03-024Revance Therapeutics, Inc. (RVNC)Sale (S): 3,201 @ $33.50EDGAR
2023-02-164Revance Therapeutics, Inc. (RVNC)Tax withholding (F): 2,085 @ $33.21EDGAR
2023-02-024Revance Therapeutics, Inc. (RVNC)Sale (S): 3,201 @ $34.60 · Grant/award (A): 50,435 (derivative) @ $0EDGAR
2023-01-234Revance Therapeutics, Inc. (RVNC)Sale (S): 1,000 @ $31EDGAR
2023-01-104Revance Therapeutics, Inc. (RVNC)Sale (S): 1,701 @ $25 · Sale (S): 1,000 @ $28 · Sale (S): 1,000 @ $30EDGAR
2023-01-034Revance Therapeutics, Inc. (RVNC)Grant/award (A): 645 @ $12.18EDGAR
2022-12-164Revance Therapeutics, Inc. (RVNC)Tax withholding (F): 1,557 @ $21.50EDGAR
2022-07-054Revance Therapeutics, Inc. (RVNC)Grant/award (A): 965 @ $11.75EDGAR
2022-03-174Revance Therapeutics, Inc. (RVNC)Tax withholding (F): 2,607 @ $15.79EDGAR
2022-02-174Revance Therapeutics, Inc. (RVNC)Tax withholding (F): 2,241 @ $13.35 · Tax withholding (F): 683 @ $13.35EDGAR
2022-02-044Revance Therapeutics, Inc. (RVNC)Grant/award (A): 68,093 (derivative) @ $0EDGAR
2022-01-044Revance Therapeutics, Inc. (RVNC)Other (J): 404 @ $13.87EDGAR
2021-12-174Revance Therapeutics, Inc. (RVNC)Tax withholding (F): 1,556 @ $15.92EDGAR
2021-07-024Revance Therapeutics, Inc. (RVNC)Other (J): 446 @ $24.09EDGAR
2021-02-194Revance Therapeutics, Inc. (RVNC)Tax withholding (F): 684 @ $28.97 · Tax withholding (F): 1,973 @ $28.97EDGAR
2021-02-044Revance Therapeutics, Inc. (RVNC)Grant/award (A): 22,620 @ $0 · Grant/award (A): 40,925 (derivative) @ $0EDGAR
2021-01-044Revance Therapeutics, Inc. (RVNC)Other (J): 493 @ $21.36EDGAR
2020-12-224Revance Therapeutics, Inc. (RVNC)Tax withholding (F): 1,556 @ $26.75EDGAR
2020-10-024Revance Therapeutics, Inc. (RVNC)Grant/award (A): 15,750 @ $0 · Tax withholding (F): 5,446 @ $25.14EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-28 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1678984 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs